Reduced expression of the adhesion molecule E-cadherin has been associated with increased invasiveness and poorer survival in patients with bladder cancer. We have examined soluble E-cadherin (sE-cadherin) and total protein concentrations in urine from patients with bladder cancer (n = 34), non-neoplastic benign urological diseases (n = 14) and healthy controls (n = 21) to determine their diagnostic and prognostic significance. Soluble E-cadherin concentrations of the cancer group were significantly higher (P < 0.001) than those of the controls but the benign group was not significantly different from either the cancer group or the controls. When sE-cadherin concentrations were adjusted for creatinine, similar but more statistically significant results were obtained and the benign group was significantly elevated compared with the controls (P < 0.01). No differences were apparent between the invasive (pT1–4) and non-invasive (pTa) cancers. Urinary total protein concentrations in the cancer group were significantly higher than the controls (P < 0.001) and the benign group (P < 0.05) although no difference was seen between the benign group and patients with non-invasive (pTa) cancer or between the benign group and controls. When expressed as the protein/creatinine index, results were similar but more statistically significant and a significant difference was seen between invasive and non-invasive cancers (P < 0.01). Only the protein/creatinine index correlated significantly with stage of the tumour (P < 0.01). It is concluded that urinary sE-cadherin measurements are of no greater value than urinary total protein.
Banks, R. E., Porter, W. H., Whelan, P., Smith, P. H. & Selby, P. J. (1995) Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Path 48: 179–180.
Becker, K. F. & Hofler, H. (1995) Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 87: 1082–1084.
Bringuier, P. P., Umbas, R., Schaafsma, H. E., Karthaus, H. F. M., Debrugne, F. M. J. & Schalken, J. A. (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumours. Cancer Res 53: 3241–3245.
Caliskan, M., Turkeri, L. N., Mansuroglu, B., Toktas, G., Aksoy, B., Uncluer, E. & Akdas, A. (1997) Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 79: 373–377.
Cancer Research Campaign Factsheet 9.1 (1997). Cancer Research Campaign, London
Damsky, C. H., Richa, J., Solter, D., Knudsen, K. & Buck, C. A. (1983) Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue. Cell 34: 455–466.
D’Hallewin, M. A. & Baert, L. (1996) Initial evaluation of the bladder tumour antigen test in superficial bladder cancer. J Urol 155: 475–476.
Dyson, E. H., Will, E. J., Davidson, A. M., O’Malley, A. H., Shepard, H. T. & Jones, R. G. (1992) Use of the urinary protein creatinine index to assess proteinuria in renal transplant patients. Nephrol Dial Transplant 7: 450–452.
Esrig, D., Elmajian, D., Groshen, S., Freeman, J., Stein, J., Chen, S. C., Nichols, P., Skinner, D., Jones, P. & Cote, R. (1994) Accumulation of nuclear p53 and tumour progression in bladder cancer. N Engl J Med 331: 1259–1264.
Gearing, A. J. H. & Newman, W. (1993) Circulating adhesion molecules in disease. Immunol Today 14: 506–512.
Gohji, K., Fujimoto, N., Ohkawa, J., Fujii, A. & Nakajima, M. (1998) Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 77: 650–655.
Griffiths, T. R. L., Brotherick, I., Bishop, R. I., White, M. D., McKenna, D. M., Horne, C. H. W., Shenton, B. K., Neal, D. E. & Mellon, J. K. (1996) Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 74: 579–584.
Hemmingsen, L., Rasmussen, F., Skaarup, P. & Wolf, H. (1981) Urinary protein profiles in patients with urothelial bladder tumours. Br J Urol 53: 324–329.
Hermanek, P. & Sobin, L. H. (eds) (1987). UICC TNM Classification of Malignant Tumours , 4th edn, pp. 65–67. Springer Verlag: Berlin
Hiraguri, S., Godfrey, T., Nakamura, H., Graff, J., Collins, C., Shayesteh, L., Doggett, N., Johnson, K., Wheelock, M., Herman, J., Baylin, S., Pinkel, D. & Gray, J. (1988) Mechanisms of inactivation of E-Cadherin in breast cancer cell lines. Cancer Res 58: 1972–1977.
Hudson, M. A. & Catalona, W. J. (1996). Urothelial tumours of the bladder, upper tracts and prostate. In Adult and Paediatric Urology, Gillenwater JY, Grayhack JT, Howards SS and Duckett JW (eds), pp. 643–694. Mosby: St Louis, MO
Johansson, B. (1975) Urinary protein patterns in patients with uroepithelial tumours. Scand J Urol Nephrol 9: 221–225.
Johansson, B. & Kistner, S. (1975) Proteinuria in patients with uroepithelial tumours with special regard to tumour size, clinical staging and grade of malignancy. Scand J Urol Nephrol 9: 45–49.
Jones, L. W., Levin, A. & Fudenberg, H. H. (1975) Glomerular antigen complexes associated with transitional cell carcinoma. Surg Gynecol Obstet 140: 896–898.
Kanai, Y., Oda, T., Tsuda, H., Ochiai, A. & Hirohashi, S. (1994) Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res 85: 1035–1039.
Kanayama, H., Yokota, K., Kurokawa, Y., Murakami, Y., Nishitani, M. & Kagawa, S. (1998) Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82: 1359–1366.
Katayama, M., Hirai, S., Kamihagi, K., Nakagawa, K., Yasumoto, M. & Kato, I. (1994a) Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 69: 580–585.
Katayama, M., Hirai, S., Yasumoto, M., Nishikawa, K., Nagata, S., Otsuka, M., Kamihagi, K. & Kato, I. (1994b) Soluble fragments of E-cadherin cell adhesion molecule increase in urinary excretion of cancer patients, potentially indicating its shedding from epithelial tumour cells. Int J Oncol 5: 1049–1057.
Kinoshita, H., Ogawa, O., Kakehi, Y., Mishina, M., Mitsumori, K., Itoh, N., Yamada, H., Terachi, T. & Yoshida, O. (1997) Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 89: 724–730.
Leyh, H., Hall, R., Mazeman, E. & Blumenstein, B. (1997) Comparison of the BARD BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology 50: 49–53.
Lipponen, P. K. & Eskelinen, M. J. (1995) Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121: 303–308.
Mao, L., Schoenberg, M., Scicchitano, M., Erozan, Y., Merlo, A., Schwab, D. & Sidransky, D. (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271: 659–662.
Matsuura, K., Kawanishi, J., Fujii, S., Imamura, M., Hiranos, S., Takeichi, M. & Niitsu, Y. (1992) Altered expression of E-cadherin in gastric cancer tissue and carcinomatous fluid. Br J Cancer 66: 1122–1130.
Mitchell, S., Sheldon, T. & Shaw, A. (1993) Quantification of proteinuria: a re-evaluation of the protein/creatinine ratio for elderly subjects. Age Ageing 22: 443–449.
Mostofi, F. K., Sobin, L. H. & Torloni, H. (1973). Histological typing of urinary bladder tumours. In International Histological Classification of Tumours, 10: World Health Organization: Geneva
O’Brien, P., Gozzo, J., Cronin, W. & Monaco, A. (1980) Qualitative analysis of proteinuria associated with bladder cancer. Invest Urol 17: 28–32.
O’Brien, P., Gozzo, J. J. & Monaco, A. P. (1981) Urinary proteins as biological markers: bladder cancer diagnosis versus urinary tract infection. J Urol 124: 802–803.
Otto, T., Birchmeier, W., Schmidt, U., Hinke, A., Schipper, J., Rubben, H. & Raz, A. (1994) Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54: 3120–3123.
Ozawa, M., Engel, J. & Kemler, R. (1990) Single amino acid substitutions in one Ca2+ binding site of uvomorulin abolish adhesive function. Cell 63: 1033–1038.
Parmar, M. K. B., Freedman, L. S., Hargreave, T. B. & Tolley, D. A. (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142: 284–288.
Reading, J., Hall, R. R. & Parmar, M. K. B. (1995) The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. Br J Urol 75: 604–607.
Rock, R. C., Walker, W. G. & Jennings, C. D. (1986). Nitrogen metabolites and renal function. In Textbook of Clinical Chemistry, Tietz NW (ed), pp. 1254–1316. WB Saunders: Philadelphia
Ross, J. S., Del Rosario, A. D., Figge, H. L., Sheehan, C., Fisher, H. A. G. & Bui, H. X. (1995) E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol 26: 940–944.
Sarosdy, M., deVERE White, R., Soloway, M., Sheinfeld, J., Hudson, M., Schellhammer, P., Jarowenko, M., Adams, G. & Blumenstein, B. (1995) Results of a multicentre trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154: 379–384.
Shimoyama, Y., Nagafuchi, A., Fujita, S., Gotoh, M., Takeichi, M., Tsukita, S. & Hirohashi, S. (1992) Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α-catenin expression in reduced cell–cell adhesiveness. Cancer Res 52: 5770–5774.
Soloway, M., Briggman, J., Carpinito, G., Chodak, G., Church, P., Lamm, D., Lange, P., Messing, E., Pasciak, R., Reservitz, G., Rukstalis, D., Sarosdy, M., Stadler, W., Thiel, R. & Hayden, C. (1996) Use of a new tumour marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363–367.
Steiner, G., Schoenberg, M. P., Linn, J. F., Mao, L. & Sidransky, D. (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3: 621–624.
Syrigos, K., Krausz, T., Waxman, J., Pandha, H., Rowlinson-Busza, G., Verne, J., Epenetos, A. & Pignatelli, M. (1995) E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer 64: 367–370.
Takeichi, M. (1990) Cadherins: a molecular family important in selective cell–cell adhesion. Ann Rev Biochem 59: 237–252.
Takeichi, M. (1993) Cadherins in cancer implications for invasion and metastasis. Curr Opin Cell Biol 5: 806–811.
Tsuji, M., Kojima, Y., Murakami, Y., Kanayama, H. & Kagawa, S. (1997) Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 79: 367–372.
Yoshida, K., Sugino, T., Tahara, H., Woodman, A., Bolodeoku, J., Nargund, V., Fellows, G., Goodison, S., Tahara, E. & Tarin, D. (1997) Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 79: 362–369.
Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T. & Hirohashi, S. (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416–7419.
Departments of Chemical Pathology, St James’s University Hospital, Leeds, LS9 7TF, UK
About this article
Cite this article
Protheroe, A., Banks, R., Mzimba, M. et al. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer. Br J Cancer 80, 273–278 (1999). https://doi.org/10.1038/sj.bjc.6690351
- soluble adhesion molecules
Scientific Reports (2021)
Molecular Biology Reports (2011)
Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma
Laboratory Investigation (2007)
Clinical & Experimental Metastasis (2007)
Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer
British Journal of Cancer (2005)